The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.
 
HANG QUACH
Consulting or Advisory Role - Amgen; Antengene; Bristol-Myers Squibb/Celgene; Celgene; CSL Behring; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Pfizer; Roche; Sanofi
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
 
Nizar J. Bahlis
Honoraria - Abbvie; Amgen; Celgene; Genentech/Roche; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda
Research Funding - Celgene (Inst); Janssen (Inst)
 
Paula Rodríguez-Otero
Honoraria - Abbvie; Celgene; GlaxoSmithKline; H3 Biomedicine; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; BMS; GlaxoSmithKline; Janssen; Pfizer; Sanofi
Speakers' Bureau - BMS; GlaxoSmithKline; Janssen; Sanofi
Travel, Accommodations, Expenses - Pfizer
 
Andrea Viqueira
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Shen-Wu Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Sangeetha Sathaiah
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Douglas M Robinson
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Thomas O'Brien
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Katja Weisel
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene (Inst); Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Janssen-Cilag; Karyopharm Therapeutics; Novartis; Oncopeptides; Pfizer; Roche; Sanofi; Sanofi (Inst); Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Oncopeptides; Roche; Sanofi; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda